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SUMMARY
Objective: An endodermal sinus tumor (EST) of the ovary and a contralateral dermoid cyst occur rarely in
pregnancy. Alternative treatment for reducing the long-term sequelae in both the mother and fetus should
be considered during pregnancy.
Case Report: At 27 weeks of gestation, a patient was diagnosed with advanced EST, FIGO (International
Federation of Gynecology and Obstetrics) stage IIIc, by magnetic resonance imaging and surgery. Following
optimal debulking surgery, three cycles of multi-agent chemotherapy, consisting of 25 mg/m2 cisplatin and
100 mg/m2 etoposide on days 1 to 4, were instituted at 21-day intervals. Maternal serum α-fetoprotein and
CA125 titers soon returned to normal pregnancy levels. A healthy male infant was delivered at 38 weeks of
gestation by cesarean section, after which a second-look laparotomy was performed. The micropathologic
findings were negative for malignancy, except that a dermoid tumor of the right ovary was confirmed.
Consolidation treatment with two cycles of chemotherapy, consisting of 20 mg/m2 cisplatin and 100 mg/m2
etoposide on days 1 to 5 and a total of 30 mg/day of bleomycin on days 6 and 7, was administered at 28-
day intervals. The patient had no evidence of disease for 16 months, and her infant son has shown adequate
growth and normal development.
Conclusions: For pregnant women with an EST of the ovary, the optimal treatment modalities might be initial
optimal debulking surgery followed by alternative chemotherapy, and further standard chemotherapy after
delivery. [Taiwanese J Obstet Gynecol 2004;43(2):113–119]
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Introduction
Ovarian cancer occurs rarely during pregnancy, averaging
about 1 in every 18,000 to 25,000 deliveries; it is usually
confined to the ovaries (71% stage I) [1]. A review of the
English literature from 1976 to the present revealed
eight cases of pure endodermal sinus tumor (EST) in
pregnancy, all of which were treated with chemotherapy
(Table) [2–9]; advanced disease was rare (1/8).
In about one of every 1,000 pregnancies, surgical
exploration is necessary due to an adnexal mass,
according to the American College of Obstetricians and
Gynecologists [10]. This mass is malignant in only
about 5% of cases, compared with 15% to 20% in non-
pregnant women. An adnexal mass during pregnancy
may become symptomatic in 10% to 15% of patients
as a result of torsion, rupture, or hemorrhage of the
tumor [11].
ESTs are rapidly growing tumors but are also very
chemo-sensitive. Nevertheless, cancer treatment during
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pregnancy must be individualized and may differ from
normal in order to take into account the health and
welfare of both the mother and fetus, which are at odds
when it comes to the use of chemotherapy. Experience
with combination chemotherapy has demonstrated the
maximal tumor cell kill rate possible within the range of
toxicity [12]. However, the use of more than one drug is
likely to have a more negative impact on the developing
fetus. Thus, we attempted to determine whether a new
treatment would be able to reduce the long-term sequelae
of chemotoxicity in the fetus (neurodevelopmental and
cardiopulmonary complications, etc.). The side effects
of bleomycin when used in adults include fever, intersti-
tial pneumonitis, and pulmonary fibrosis. However, the
long-term complications of bleomycin to an exposed
fetus, in which the lungs are immature before 34 weeks
of gestation, have not been adequately studied because
of the rarity of its use, and, thus, this remains a concern
[10–12].
Our patient experienced spontaneous rupture of an
advanced EST with bloody ascites and carcinomatosis
at 27 weeks of gestation. After initial debulking surgery
(< 1 cm), modified chemotherapy with cisplatin and eto-
poside during pregnancy followed by a second-look
laparotomy, she achieved micropathologic remission.
The mother and baby are well, and the infant has shown
normal growth and neurodevelopment up to the time
of writing. We considered it worthwhile to report this
rare case, presenting our experience and a follow-up
discussion.
Case Report
A 31-year-old woman, gravida 5, para 2, at 27 weeks of
gestation was referred to the emergency department of
our hospital with left upper abdominal distension and
tightness for 4 days. A huge left adnexal mass with
complex content was found on ultrasound. The left
adnexa had only been 4 cm in diameter 1 month pre-
viously. Magnetic resonance imaging (MRI) showed
an 18 × 12 × 10 cm complex mass with both solid and
Table. Reported cases of pure endodermal sinus tumor during pregnancy treated with chemotherapy
Study Gestational age Stage Chemotherapy during Maternal Delivery
at diagnosis and surgery pregnancy status at
Malone et al, 1986 [2] 25 wk Stage Ia, RSO VBP × 2 courses, then A+W 27 mo 32 wk
additional 3 courses
after delivery
Kim & Park, 1989 [3] 15 wk Stage Ic 6 courses (non-cisplatin), A+W 33 mo 37 wk
then additional 2 courses
after delivery
Metz et al, 1989 [4] 13 wk Stage I VAC × 5 courses, then A+W 12 mo Term
additional 7 courses
after delivery
Farahmand et al, 17 wk Stage I, BSO, VBP × 6 courses, but A+W 27 mo
1991 [5] omentectomy bleomycin stopped
after 4 courses
Van der Zee et al, 17 wk Stage I No chemotherapy, but 4 A+W 24 mo 33 wk
1991 [6] courses of chemotherapy
(PEB) after delivery
Elit et al, 1999 [7] 23 wk Stage II, LSO PEB × 1 course A+W 16 mo 28 wk,
ventromegaly,
cerebral atrophy
Rajendran et al, 1999 [8] 19 wk Stage Ia, RSO No chemotherapy, but A+W 12 mo 32 wk
recurrence at 32 wk
Shimizu et al, 2003 [9] 19 wk Stage Ic, SO No chemotherapy, then A+W 27 mo 36 wk
3 courses of chemotherapy
(PEB) after delivery
RSO = right salpingo-oophorectomy; VBP= vinblastine + bleomycin + cisplatin; A+W = alive and well; VAC = vincristine + actinomycin + cyclophosphamide;
BSO = bilateral salpingo-oophorectomy; LSO = left salpingo-oophorectomy; PEB = cisplatin + etoposide + bleomycin; SO = salpingo-oophorectomy.
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cystic components. Ascites was also noted (Figure 1).
No relevant personal or family history was noted. Ova-
rian malignancy was suspected.
Laboratory studies showed a lactate dehydro-
genase of 159 U/L and a serum β-human chorionic
gonadotropin of 27,765 mIU/mL. Maternal serum
α-fetoprotein (MSAFP) was markedly elevated at
4,314.77 mIU/mL (> 12 × the median for gestation)
and CA125 was 214.2 U/mL. Ultrasound revealed that
the status of the fetus was adequate for gestational
age, and showed an 11 × 10 cm complex mass thought
to be of ovarian origin.
Progressive abdominal distension and tightness, not
related to uterine contractions, were noted. Emergency
laparotomy was performed under the impression of
either acute tumor torsion of the ovarian malignancy or
spontaneous rupture with internal bleeding. Through a
midline incision, bloody ascites (1,400 mL) was found.
The tumor was 17 × 11.5 × 10 cm, with parts of multiple
cysts and a hemorrhagic solid tumor and a disrupted
capsule growing out towards the left upper abdomen
(32 cm in diameter) (Figure 2A). Disseminating tumors
on the omentum, bilateral paracolic gutters, and bladder
serosa were found. Debulking surgery included a left
salpingo-oophorectomy, a partial omentectomy, and
radical resection of tumor seedings. The residual tumors
were smaller than 1 cm. The mother and fetus were well
after surgery.
Frozen-section pathology showed EST at stage IIIc.
Micropathologically, sections showed an ovarian tumor
with nests of neoplastic hyperchromic and pleomorphic
cells that were arranged in reticular, cord-like, papillary,
or tubular structures in mucin-like pools. Schiller-Duval
bodies, hyaline bodies, and large areas of necrosis were
present (Figure 2B).
The next day, laboratory results showed that the
activated partial thromboplastin time (APTT) and plas-
ma thromboplastin (PT) were, surprisingly, elevated
(APTT/control > 120/29.2; PT/control 46.5/10.2). How-
ever, no signs or symptoms of a bleeding tendency were
found. Based on our past experience with yolk sac
tumors, prolongation of APTT and PT may be induced
by tumors and surgical manipulation. The APTT and
PT values had fallen sharply by the next day, to APTT/
control of 62.5/28.2 and PT/control of 10.2/10.2. The
APTT/control on the second postoperative day was
42.5/28.
Figure 1. Magnetic resonance image showing ascites, a mass
of intermediate signal intensity, and a fetus in the uterus.
Scattered areas of prominent high intensity represent cysts and
solid parts with hemorrhage.
Figure 2. (A) Gross appearance of the mass on a cut section.
It is a solid, soft, yellowish-white tumor with parts of multiple
cysts containing hemorrhagic or dark-fluid materials, com-
patible with the magnetic resonance image. The two white
arrows reveal the site of rupture. (B) Micropathologic view.
Nests of neoplastic hyperchromic and pleomorphic cells, a
Schiller-Duval body, and hyaline bodies are present (hema-
toxylin & eosin, original magnification × 100).
A
B
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We decided to proceed with alternative chemo-
therapy using only cisplatin (25 mg/m2/day) and
etoposide (100 mg/m2/day) for adjuvant treatment,
injected on days 1 to 4 for three 21-day cycles until
delivery. MSAFP and CA125 values were closely moni-
tored to evaluate the chemotherapeutic response
(Figure 3). Regular sonographic monitoring using Dop-
pler flow showed a normal systolic/diastolic ratio and
a normal amniotic fluid index, but the fetus was the size
of one of 3 weeks’ less gestational age.
At 38 weeks of gestation, cesarean section and
second-look laparotomy were performed. A 2,180 g
male infant (< 5th percentile) was delivered; 1 and 5
minute Apgar scores were 8 and 9, respectively. No
gross fetal anomalies were identified. In the mother,
many scattered tiny papillary nodularities were found,
disseminated throughout the abdominopelvic cavity,
especially on the intestinal surface. No additional ascites
was found. Surgery included total hysterectomy, bilate-
ral salpingo-oophorectomy, appendectomy, retroperi-
toneal lymph node sampling, and excision of all the tiny
scattered nodularities and adhesive bands on the peri-
toneal surfaces of the intestines, pelvis, and abdomen.
The final pathology report showed no residual EST
tissue, but there was a 3.7 × 2.0 × 1.0 cm dermoid
cyst on the right ovary. MSAFP concentration was
58.8 ng/mL and the CA125 concentration was 42.3 µ/mL
5 days postoperatively. Two-cycle adjuvant chemo-
therapy with the addition of bleomycin was given to
consolidate the cancer treatment. Cisplatin 20 mg/m2
and etoposide 100 mg/m2 were given for 5 days, fol-
lowed by 30 mg bleomycin on days 6 and 7. Side ef-
fects of bleomycin chemotherapy included maternal
fever, leukocytosis, and chest distress on day 7 of
each course. The newborn baby suffered from growth
restriction, hypoglycemia, and physiologic hyperbiliru-
binemia that was treated using phototherapy, but he
did not develop leukocytopenia or thrombocytopenia.
He has demonstrated normal growth up to the time
of writing. The mother has also been disease-free for
16 months.
Discussion
The incidence of ovarian cancer in pregnancy varies
widely in the literature, from 1 in 8,000 to 1 in 12,000
deliveries. About 44% of ovarian tumors during preg-
nancy are diagnosed in the first trimester, 17% during
the second, 17% during the third trimester or at the
time of cesarean section, and 22% during puerperium.
However, only 3% to 6% of adnexal masses are true
malignant neoplasms, including germ-cell (30–33%)
and epithelial-cell (35–40%) malignancies [12]. ESTs
are the second most frequent type of ovarian germ-
cell tumor, the most aggressive and rapid-growing
neoplasm, and are rarely found at an advanced stage
during pregnancy.
Standard treatment for an EST consists of cyto-
reductive surgery with either adjuvant or therapeu-
tic chemotherapy. Cisplatin-containing combination
chemotherapy, preferably BEP (bleomycin, etoposide,
and cisplatin) or POMB-ACE (cisplatin, vincristine,
methotrexate, bleomycin, actinomycin, cyclophos-
phamide, and etoposide), should be used as primary
chemotherapy. The introduction of multi-agent chemo-
therapy has revolutionized the treatment of malig-
nant ovarian germ-cell tumors and can cure most ad-
vanced disease in more than 80% of patients.
Based on a review of the literature, exposure during
the second and third trimesters leads to a 1.3% inci-
dence of fetal malformations and to non-teratogenic
sequelae (e.g. intrauterine growth restriction, neuro-
developmental complications of the central nervous
systems) [7,13]. However, the long-term delayed effects
on the infant’s hematologic, cardiac, and pulmonary
systems, and on fertility, have yet to be described. The
side effects of bleomycin include interstitial pneumo-
nitis, fever, and pulmonary fibrosis, all of which were
experienced by the mother in this case. In 1991, Loehrer
et al conducted a randomized study of three cycles of
etoposide plus cisplatin with or without bleomycin in
166 patients with germ-cell tumors of the testes [14].
They found that the BEP regimen had a relapse-free
survival rate of 84%, compared with 69% for the cispla-
tin and etoposide regimen (p = 0.03). Therefore, we
tried an alternative chemotherapeutic strategy in which
bleomycin was not used during the pregnancy but was
Figure 3. Regression of maternal serum α-fetoprotein (MSAFP)
levels through the course of therapy.
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added after delivery, leading to final successful patho-
logic remission of the EST. Thus, alternative cisplatin-
based chemotherapy may be considered after opti-
mal surgery and with strict follow-up of tumor mar-
kers to eliminate, as far as possible, the side effects of
multiple chemotherapeutic agents on fetuses.
Elevated MSAFP can result from pregnancy-related
sources, as noted by Horbelt et al [15]. Extremely high
MSAFP levels (> 9 multiples of the median) in the ab-
sence of fetal abdominal wall defects and anencephaly
should raise the possibility of germ-cell tumors of either
gonadal or extragonadal origin [15,16]. Extragonadal
origins include non-malignant (hepatitis and inflamma-
tory bowel disease) and malignant conditions (hepa-
tocellular carcinoma). MRI is now routinely used to
evaluate focal and diffuse hepatic disease in both non-
pregnant and pregnant women. In our case, MRI ex-
cluded a hepatic pathology. Non-pregnant women
have very low to nondetectable serum α-fetoprotein
levels (usually < 2 ng/mL), and all α-fetoprotein in ex-
cess of basal levels found during pregnancy is thought
to originate from the fetus. Bergstrand and Czar
demonstrated that MSAFP rises rapidly in the second
trimester, reaching a maximum at about 32 weeks,
and then declines until birth, when it is approximately
55 ng/mL. After birth, MSAFP rapidly disappears
from the serum, and 3 weeks after full-term delivery,
it can be detected only in very small amounts (0–
15 ng/mL) [17]. In our case, the MSAFP and CA125
levels declined rapidly and reached a 75% response
rate after the first chemotherapy course. This encouraged
us to continue to administer this chemotherapeutic
regimen. The tumor markers were close to normal and
were compatible with the micropathologic findings
from surgical exploration. Thus, we consider that,
when there is an EST during pregnancy, MSAFP and
CA125 are good follow-up markers to evaluate che-
motherapeutic potency and response rate.
EST should be considered in the differential diagnosis
of a complex abdominal mass in girls and young women.
The cut surface of the tumor has cystic and solid areas,
as well as extensive areas of hemorrhage and necrosis.
On sonography and computed tomography (CT), EST
presents as a large, complex abdominal mass, with the
cystic components more visible on CT. ESTs are well-
enhanced solid tumors on both CT and MRI. However,
compared with CT findings, these tumors in MRI studies
are associated with striking enhancement and numerous
signal voids (because of their hypervascular nature),
areas of hemorrhage that exhibit a high intensity on T1-
weighted MRI, and heterogeneous high intensity (re-
flecting edematous stroma, cysts, and hemorrhage) on
T2-weighted MRI, as in our case [18–20].
A coagulatory disorder may be strongly related to
angiogenesis and tumor progression. Cancer patients
may experience problems with hemostasis due to
coagulation factor inhibitors or fibrinolytic activators
produced by the neoplasm. Some tumors directly syn-
thesize inhibitors, whereas others produce inhibitors
via tumor necrosis. In either case, these inhibitors cause
dysfunction of naturally occurring coagulation factors
and coagulopathies ensue, leading to disseminated
intravascular coagulation (DIC). DIC is noted most
frequently in the latter phases of malignancy, when the
host is debilitated and the neoplasm widespread.
Chronic DIC, which occurs less frequently, may present
with only laboratory abnormalities, such as APTT and
PT, as evidence of the ongoing process. As with other
cancer-related coagulopathies, successful treatment
of DIC consists of eliminating the underlying neoplasm,
as in our case [21].
In a normal pregnancy, the components of coa-
gulation and blood volume are altered to facilitate
hemostasis. Factors I (fibrinogen), VII, VIII, IX, and X are
elevated, but changes in the platelet count are negligible.
When stress such as hemorrhage occurs, plasminogen-
to-plasmin conversion is stimulated, initiating coagu-
lation and fibrinolysis. However, the incidence of DIC
in obstetric patients is difficult to ascertain owing to
the wide variation in precipitating events and the
exceedingly complex range of clinical manifestations.
The syndrome may occur in association with a wide
variety of obstetric complications, including pregnancy-
induced hypertension, abruptio placenta, amniotic fluid
embolism, intra-amniotic injection of saline, hemor-
rhagic shock, and sepsis [22]. No obstetric problem re-
lated to coagulopathy occurred in this case. We pos-
tulated that the DIC syndrome, especially the post-
operative laboratory abnormalities in this case, is at-
tributable to cancer induction by the advanced stage
of the EST [21,22]. However, larger studies need to
be conducted to investigate this relationship further.
An etiologic classification of some known causes
of small-for-gestational-age fetuses includes constitu-
tionally small mothers, poor maternal weight gain,
congenital fetal infections, congenital malformation,
chromosome abnormalities, severe malnutrition, vas-
cular disease, chronic renal disease, chronic hypoxia,
maternal anemia, placental and cord abnormalities,
teratogens, and drugs. Limited use of cisplatin in
pregnancy has been reported, with no known compli-
cations that can be clearly attributed to cisplatin alone
[23]. There have been no reports concerning fetal
malformation related to the use of etoposide; however,
intrauterine growth restriction and pancytopenia in
neonates have been reported [24].
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Benign cystic teratoma is associated with 5% to 10%
of malignant germ-cell tumors. However, an ipsilateral
or contralateral dermoid cyst is present in 14% of ESTs,
as in our case [25]. The pathogenic theory, which sug-
gests an origin from a primordial germ cell, is now the
most widely accepted. These tumors arise from a single
germ cell [26].
The occurrence of a malignancy during pregnancy
and the decision-making process are difficult for the
patient, her family, and the health care team. In the
third trimester, the baby can often be delivered before
beginning therapy, if the condition of the fetus is good
based on a strict evaluation. The decision-making pro-
cess, in our experience, should include the expectant
mother and her family. The consultation should include
information on fetal well-being and prematurity, the
prognosis under hospital care, the toxicities of chemo-
therapeutic agents, and the relationship between cancer,
pregnancy, and maternal outcome. Maternal outcome
is strongly associated with optimal debulking surgery
and the chemotherapeutic effect together with close
follow-up of tumor markers (AFP and CA125) if preg-
nancy is to be continued. On the other hand, delays in
initiating chemotherapy should be avoided because of
the progressive nature and fatal characteristics of
this disease. Fetal outcome is strongly related to an
assessment of fetal well-being by ultrasound and a
biophysical profile. If problems with fetal lung maturity
or fetal distress are detected or suspected, immediate
cessation of therapy is indicated.
In the rare event of ovarian cancer during pregnancy,
we suggest trying an alternative multi-agent chemo-
therapy regimen during pregnancy, based on non-
pregnancy experience for cancer treatment, then
changing to standard treatment after delivery. The
potential benefits of alternative chemotherapy with
deletion of bleomycin include not only reduced long-
term undesirable toxicities to the fetus and mother
without significantly compromising anti-tumor acti-
vity, but also the reduced possibility of consequent
multidrug resistance. Further evaluation is required to
confirm the activity and therapeutic index, and to
determine the optimal dose and schedule to be used
in a pregnancy with ovarian cancer.
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